Findings of Research Misconduct, 45663-45664 [2015-18756]
Download as PDF
<![CDATA[
45663
Federal Register / Vol. 80, No. 147 / Friday, July 31, 2015 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS—Continued
Form name
Follow-Up Survey ..............................
Follow-Up Survey ..............................
Focus Groups ...................................
Key Informant Interviews ..................
Key Informant Interviews ..................
Total ...........................................
Health and Health Care
sionals.
Community Health Workers
Health and Health Care
sionals.
Health and Health Care
sionals.
Community Health Workers
1.00
10/60
701
.............
Profes-
6
15
2.00
1.00
10/60
120/60
2
29
Profes-
13
1.00
60/60
13
.............
25
1.00
60/60
25
...........................................................
23187
........................
........................
2031
[FR Doc. 2015–18810 Filed 7–30–15; 8:45 am]
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
`
Julie Masse, Pennsylvania State
University (PSU): Based on an
assessment conducted by the
Pennsylvania State University College of
Medicine (PSU–COM) and the
Respondent’s admission, ORI and PSU
`
found that Ms. Julie Masse, former
postdoctoral scholar, PSU–COM,
engaged in research misconduct in
research supported by National Cancer
Institute (NCI), National Institutes of
Health (NIH), grant 4 R00 CA138498.
ORI found that the Respondent
knowingly engaged in research
misconduct by falsifying and/or
fabricating Western blot data and
analyses that were including in the
following manuscript:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:44 Jul 30, 2015
Total burden
(hours)
4208
Darius Taylor,
Paperwork Reduction Act Clearance Officer.
ACTION:
Average
burden per
response
(hours)
Profes-
OS specifically requests comments on
(1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
AGENCY:
Number
responses per
respondent
Number of
respondents
Type of respondent
Jkt 235001
• ‘‘Cellular invasion following p120catenin loss is mediated by AP-1, ITGA2
and MMP11,’’ submitted to Molecular
Cancer Research (hereafter referred to as
the ‘‘Molecular Cancer Research
manuscript’’).
ORI found that the Respondent
knowingly falsified and/or fabricated
Western blot images, by manipulating
the images to give the desired results,
and quantitative PCR data and cell
invasion and migration data, which
were included in Figures 2, 3, S1, and
S2 in the Molecular Cancer Research
manuscript.
Specifically, ORI found that the
Respondent included falsified and/or
fabricated data and images in the
following figures, and the corresponding
text, in the Molecular Cancer Research
manuscript:
1. Bands were cut and pasted from
different Western blots for the following
figures:
a. Figures 2A, lanes 2 and 3, for PcJun (S73)
b. Figure 2D, lanes 4 and 6, bands
identified as ITGA2
c. Figure 3B, bands identified as
ITGA2 and MMP11
d. Figure 3D, bands identified as
ITGA2 and MMP11 for lanes M2Neo↑ITGA2 control and ↓MMP1
e. Figure 3E, bands identified as
ITGA2 and MMP11 for lanes M2KO↓ITGA2 control and M2KO-↓ITGA2↑MMP11
f. Figure S1A, bands identified as PcJun (S73)
g. Figure S2A, bands identified as PcJun (S73)
h. Figure S2C, bands identified as PcJun (S73)
i. Figure S2E, bands identified ITGA2
and MMP11
j. Figures S4B and C, identical bands
were used for b-actin
2. Numbers were increased or
decreased in cell invasion and migration
assays to give the desired results in the
following figures:
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
a. Figure 2B, for M2KO-DMSO cells
and M2KO-SR11302 cells
b. Figure 3F, for M2Neo-↑ITGA2
↓MMP11
c. Figure 3G, for M2KO-↓ITGA2
↑MMP11
d. Figure S1B, for F2KO-cJun peptide
e. Figure S2B, for F2KO-cJun DMSO
and F2KO-cJun SR11302
f. Figure S2D, for F2KO-cJun peptide
g. Figure S2F, for F2Tom-↑ITGA2 and
F2KO-↓ITGA2 peptide
h. Figures S4A, B, C, and D, for the
migration for M2KO and F2KO cells
3. qPCR numbers were altered in
Figure 2C, for M2KO-DMSO-PcJun ChIP
and for M2KO-SR11302-PcJun ChIP, to
give the desired result of PcJun binding
to ITGA2 promoter.
`
Ms. Masse has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed for a period of
two (2) years, beginning on July 6, 2015:
(1) To have her research supervised;
Respondent agreed that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which her
participation is proposed and prior to
her participation in any capacity on
PHS-supported research, Respondent
shall ensure that a plan for supervision
of her duties is submitted to ORI for
approval; the supervision plan must be
designed to ensure the scientific
integrity of her research contribution;
Respondent agreed that she will not
participate in any PHS-supported
research until such a supervision plan is
submitted to and approved by ORI;
Respondent agreed to maintain
responsibility for compliance with the
agreed upon supervision plan;
(2) that any institution employing her
shall submit in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
E:\FR\FM\31JYN1.SGM
31JYN1
45664
Federal Register / Vol. 80, No. 147 / Friday, July 31, 2015 / Notices
experiments or are otherwise
legitimately derived, and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 27, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–18752 Filed 7–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Donald Wright,
Acting Director, Office of Research Integrity.
Submission for OMB Review; 30-Day
Comment Request; New Assessment
of NHLBI’s Global Health Initiative
Collaborating Centers of Excellence
[FR Doc. 2015–18756 Filed 7–30–15; 8:45 am]
SUMMARY:
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
asabaliauskas on DSK5VPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Peer Review Meeting.
Date: August 24–25, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Susana, DVM, Ph.D.
Mendez, Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, Room 3G53B, National Institutes
of Health, NIAID, 5601 Fishers Lane Dr. MSC
9823, Bethesda, MD 20892–9823, (240) 669–
5077, mendezs@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
VerDate Sep<11>2014
17:44 Jul 30, 2015
Jkt 235001
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on 3/13/2015,
document number 2015–05722, pages
13396–13397. One comment was
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Heart, Lung and
Blood Institute (NHLBI), National
Institutes of Health, may not conduct or
sponsor, and the respondent is not
required to respond to, an information
collection that has been extended,
revised, or implemented on or after
October 1, 1995, unless it displays a
currently valid OMB control number.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, OIRA_submission@
omb.eop.gov or by fax to 202–395–6974,
Attention: NIH Desk Officer.
DATES: Comment Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30-days of the date of
this publication.
FOR FURTHER INFORMATION CONTACT: To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Ms. Deshiree Belis, National
Heart, Lung, and Blood Institute,
National Institutes of Health, 6705
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Rockledge Dr., Suite 6185A, Bethesda,
MD 20892, or call non-toll-free number
301–435–1032, or Email your request,
including your address to
deshiree.belis@nih.gov. Formal requests
for additional plans and instruments
must be requested in writing.
Proposed Collection: New Assessment
of NHLBI’s Global Health Initiative
Collaborating Centers of Excellence
(NHLBI), 0925—New, National Heart,
Lung, and Blood Institute (NHLBI), the
National Institutes of Health (NIH).
Need and Use of Information
Collection: This collection proposes to
conduct a one-time outcome evaluation
of the NHLBI Global Health Initiative
Centers of Excellence (GHI COE)
Program to examine the extent to which
the program achieved its intended
objectives in developing sustainable
research and research training capacity,
and advancing information about the
prevention and treatment of chronic
non-communicable chronic
cardiovascular and pulmonary diseases
(CVPD) in low- and middle-income
country (LMIC) populations. The
outcome evaluation will utilize a mixedmethods approach to comprehend each
COE’s processes, short term outcomes,
and sustainability outcomes/efforts.
Specifically, the evaluation will involve
triangulating quantitative data sources
(e.g., archived systematic reporting
data), and qualitative data sources (e.g.,
archival data and key informant
interview data). Data collected will be
used to develop a Case Study report for
each COE outlining their experience
with implementing their program as
well as a comprehensive cross-site
Lessons Learned Report describing
knowledge and experiences from the
overall program, including similarities
and differences across a variety of
project settings and conditions.
Findings from interviews will be
incorporated into the Case Studies
report and Lessons Learned report,
which will be used by CTRIS to inform
NHLBI and NIH stakeholders about
structural issues relevant to planning
both global and domestic biomedical
research and training programs with
diverse operational conditions and
challenges. Additionally, COEs may
utilize the Case Studies report as a
marketing tool to attract additional
funding and media coverage.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
36.
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 80, Number 147 (Friday, July 31, 2015)]
[Notices]
[Pages 45663-45664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-18756]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Julie Mass[egrave], Pennsylvania State University (PSU): Based on
an assessment conducted by the Pennsylvania State University College of
Medicine (PSU-COM) and the Respondent's admission, ORI and PSU found
that Ms. Julie Mass[egrave], former postdoctoral scholar, PSU-COM,
engaged in research misconduct in research supported by National Cancer
Institute (NCI), National Institutes of Health (NIH), grant 4 R00
CA138498.
ORI found that the Respondent knowingly engaged in research
misconduct by falsifying and/or fabricating Western blot data and
analyses that were including in the following manuscript:
``Cellular invasion following p120-catenin loss is
mediated by AP-1, ITGA2 and MMP11,'' submitted to Molecular Cancer
Research (hereafter referred to as the ``Molecular Cancer Research
manuscript'').
ORI found that the Respondent knowingly falsified and/or fabricated
Western blot images, by manipulating the images to give the desired
results, and quantitative PCR data and cell invasion and migration
data, which were included in Figures 2, 3, S1, and S2 in the Molecular
Cancer Research manuscript.
Specifically, ORI found that the Respondent included falsified and/
or fabricated data and images in the following figures, and the
corresponding text, in the Molecular Cancer Research manuscript:
1. Bands were cut and pasted from different Western blots for the
following figures:
a. Figures 2A, lanes 2 and 3, for P-cJun (S73)
b. Figure 2D, lanes 4 and 6, bands identified as ITGA2
c. Figure 3B, bands identified as ITGA2 and MMP11
d. Figure 3D, bands identified as ITGA2 and MMP11 for lanes M2Neo-
[uarr]ITGA2 control and [darr]MMP1
e. Figure 3E, bands identified as ITGA2 and MMP11 for lanes M2KO-
[darr]ITGA2 control and M2KO-[darr]ITGA2-[uarr]MMP11
f. Figure S1A, bands identified as P-cJun (S73)
g. Figure S2A, bands identified as P-cJun (S73)
h. Figure S2C, bands identified as P-cJun (S73)
i. Figure S2E, bands identified ITGA2 and MMP11
j. Figures S4B and C, identical bands were used for [beta]-actin
2. Numbers were increased or decreased in cell invasion and
migration assays to give the desired results in the following figures:
a. Figure 2B, for M2KO-DMSO cells and M2KO-SR11302 cells
b. Figure 3F, for M2Neo-[uarr]ITGA2 [darr]MMP11
c. Figure 3G, for M2KO-[darr]ITGA2 [uarr]MMP11
d. Figure S1B, for F2KO-cJun peptide
e. Figure S2B, for F2KO-cJun DMSO and F2KO-cJun SR11302
f. Figure S2D, for F2KO-cJun peptide
g. Figure S2F, for F2Tom-[uarr]ITGA2 and F2KO-[darr]ITGA2 peptide
h. Figures S4A, B, C, and D, for the migration for M2KO and F2KO
cells
3. qPCR numbers were altered in Figure 2C, for M2KO-DMSO-PcJun ChIP
and for M2KO-SR11302-PcJun ChIP, to give the desired result of PcJun
binding to ITGA2 promoter.
Ms. Mass[egrave] has entered into a Voluntary Settlement Agreement
and has voluntarily agreed for a period of two (2) years, beginning on
July 6, 2015:
(1) To have her research supervised; Respondent agreed that prior
to the submission of an application for U.S. Public Health Service
(PHS) support for a research project on which her participation is
proposed and prior to her participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision
of her duties is submitted to ORI for approval; the supervision plan
must be designed to ensure the scientific integrity of her research
contribution; Respondent agreed that she will not participate in any
PHS-supported research until such a supervision plan is submitted to
and approved by ORI; Respondent agreed to maintain responsibility for
compliance with the agreed upon supervision plan;
(2) that any institution employing her shall submit in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual
[[Page 45664]]
experiments or are otherwise legitimately derived, and that the data,
procedures, and methodology are accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant.
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-18756 Filed 7-30-15; 8:45 am]
BILLING CODE 4150-31-P
